Preoperative chemotherapy for women with operable breast cancer

被引:292
作者
Mieog, J. S. D. [1 ]
van der Hage, J. A. [1 ]
van de Velde, C. J. H. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RA Leiden, Netherlands
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2007年 / 02期
关键词
D O I
10.1002/14651858.CD005002.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Currently, preoperative chemotherapy is the standard of care in locally advanced breast cancer to achieve local tumour downsizing in order to make surgery possible. Since the early 1980s, the role of preoperative chemotherapy in early stage (or operable) breast cancer has been the subject of study. Potential advantages are early introduction of systemic therapy, determination of chemosensitivity, reduction of tumour volume and downstaging of surgical requirement. Concerns exist about local control after downsized surgery and the delay of local treatment in patients with tumours resistant to chemotherapy. Objectives To assess the effectiveness of preoperative chemotherapy in women with operable breast cancer when compared to postoperative chemotherapy. Search strategy The Specialised Register maintained by the Editorial Base of the Cochrane Breast Cancer Group was searched on 4th of August 2005. Selection criteria Randomised trials comparing preoperative chemotherapy with postoperative in women with operable breast cancer. Data collection and analysis Studies were assessed for eligibility and quality, and data were extracted by two independent review authors. Hazard ratios were derived for time-to-event outcomes directly or indirectly using the methods described by Parmar. Relative risks were derived for dichotomous outcomes. Meta-analyses were performed using fixed effect model. Main results We identified 14 eligible studies which randomised a total of 5,500 women. Median follow-up ranged from 18 to 124 months. Eight studies described a satisfactory method of randomisation. Data, based on 1139 estimated deaths in 4620 women available for analysis, show equivalent overall survival rates with a HR of 0.98 (95% CI, 0.87 to 1.09; p, 0.67; no heterogeneity). Preoperative chemotherapy increases breast conservation rates, yet at the associated cost of increased loco regional recurrence rates. However, this rate was not increased as long as surgery remains part of the treatment even after complete tumour regression (HR, 1.12; 95% CI, 0.92 to 1.37; p, 0.25; no heterogeneity. Preoperative chemotherapy was associated with fewer adverse effects. Pathological complete response is associated with better survival than residual disease (HR, 0.48; 95% CI, 0.33 to 0.69; p, < 10-4). Authors' conclusions This review suggests safe application of preoperative chemotherapy in the treatment of women with early stage breast cancer in order to down-stage surgical requirement, to evaluate chemosensitivity and to facilitate translational research.
引用
收藏
页数:57
相关论文
共 87 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]  
Abraham DC, 1996, CANCER, V78, P91, DOI 10.1002/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO
[3]  
2-2
[4]   Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients [J].
Arriagada, R ;
Lê, MG ;
Guinebretière, JM ;
Dunant, A ;
Rochard, F ;
Tursz, T .
ANNALS OF ONCOLOGY, 2003, 14 (11) :1617-1622
[5]   Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].
Ayers, M ;
Symmans, WF ;
Stec, J ;
Damokosh, AI ;
Clark, E ;
Hess, K ;
Lecocke, M ;
Metivier, J ;
Booser, D ;
Ibrahim, N ;
Valero, V ;
Royce, M ;
Arun, B ;
Whitman, G ;
Ross, J ;
Sneige, N ;
Hortobagyi, GN ;
Pusztai, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293
[6]   Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[7]  
Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19
[8]   PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].
BONADONNA, G ;
VERONESI, U ;
BRAMBILLA, C ;
FERRARI, L ;
LUINI, A ;
GRECO, M ;
BARTOLI, C ;
DEYOLDI, GC ;
ZUCALI, R ;
RILKE, F ;
ANDREOLA, S ;
SILVESTRINI, R ;
DIFRONZO, G ;
VALAGUSSA, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545
[9]   CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J].
BONADONNA, G ;
VALAGUSSA, P ;
MOLITERNI, A ;
ZAMBETTI, M ;
BRAMBILLA, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :901-906
[10]   Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy:: an updated analysis of a randomized trial [J].
Broët, P ;
Scholl, SM ;
de la Rochefordière, A ;
Fourquet, A ;
Moreau, T ;
De Rycke, Y ;
Asselain, B ;
Pouillart, P .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (02) :151-156